June 14, 2012 in Cancer An investigational drug that
acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer
is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a
partnership between Scottsdale Healthcare and the Translational Genomics
Research Institute (TGen) that treats cancer patients with promising new drugs.
The Phase 2 clinical trial tests the effectiveness and safety of INNO-206 in patients with advanced pancreatic
ductual adenocarcinomas (PDA) who have not responded to prior standard
treatment. PDA is a malignant tumor arising from the duct cells within a gland
in the pancreas, and represents about 80 percent of all pancreatic cancers. Pancreatic
cancer is extremely difficult to treat and the fourth most common cause of
cancer-related deaths in the U.S. ,
with more than 43,000 new cases reported in 2010 and 37,000 deaths attributed
to this disease each year. Tumors may grow in the pancreas without any early
symptoms, which means that the disease is often in an advanced stage when it is
diagnosed. "The drug's effectiveness works like a Trojan Horse because it
is prepared in albumin which pancreatic cancer likes to eat, thereby
transporting the drug into the cancer cells and destroying them," said
Jasgit Sachdev, M.D., of the Virginia G. Piper Cancer Center Clinical Trials. Preclinical
results showing the drug induced complete tumor remissions in the laboratory
were presented at the American Association for Cancer Research (AACR) 2012
Annual Meeting. "We are encouraged by early study results and looking
forward to the next step in evaluating the activity and safety of INNO-26 in patients with advanced pancreatic
ductual adenocarcinomas," said Dr. Ramesh Ramanathan, Medical Director of
Virginia G. Piper Cancer Center Clinical Trials, and Clinical Professor and
Deputy Director of the Clinical Translational Research Division at TGen. Los
Angeles-based CytRx holds the worldwide rights to INNO-206, which is a
tumor-targeted conjugate of the widely used chemotherapeutic agent doxorubicin.
INNO-206 has been granted orphan drug designation by the U.S. Food and Drug
Administration (FDA) for the treatment of patients with pancreatic cancer. Virginia
G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare is co-lead site
Stand Up to Cancer of the Pancreatic Cancer Dream Team, comprised of scientists
working collaboratively to develop new treatments for pancreatic cancer. TGen
Drug Development (TD2), a TGen subsidiary, is managing this Phase 2 clinical
trial on behalf of CytRx. The Phase 2 clinical trial will enroll up to 27
patients at multiple clinical sites in the U.S. The trial patients will be
treated with intravenously administered INNO-206 once every three weeks for up
to eight cycles. Trial patients will be evaluated for complete and partial
tumor responses, side effects and overall survival.
No comments:
Post a Comment